The FDA approved camizestrant plus a CDK4/6 inhibitor for hormone receptor–positive, HER2-negative metastatic breast cancer that acquires an ESR1 mutation.
News|Articles|July 16, 2025
FDA’s Published CRLs Deliver Insight Into the Drug Approval Process
Author(s)Ashling Wahner
Fact checked by: Kyle Doherty
Dive into each of the oncology-related CRLs that were recently released by the FDA, as well as relevant subsequent FDA decisions.
Advertisement
Advertisement
On July 10, 2025,
Related to this article
Brain cancer experts explain the current wave of surgical advances and advocate for team-based, multidisciplinary strategies to individualize patient care.
Huntsman Cancer Institute at the University of Utah celebrated a major milestone in the development of Huntsman Cancer Institute in Vineyard.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
A new life-years-saved methodology found blood cancer treatments saved million years of life since 1949, with future gains reliant on funding and access.
Tycel Phillips, MD, discusses sonrotoclax’s FDA approval for mantle cell lymphoma and why the BCL2 inhibitor opens more possibilities.
Daraxonrasib produced a 42% overall response rate and 16.0-month median OS in previously treated RAS-mutant NSCLC in a phase 1/2 trial.
Ivonescimab significantly improved OS vs pembrolizumab at a prespecified interim analysis of the HARMONi-2 trial in first-line PD-L1–positive NSCLC.
Advertisement
Advertisement